Faster regulatory approval has not necessarily achieved faster patient access. A new OHE paper sets out how risk-sharing can tackle this, enabling resolution of differences of view between innovators and payers about a technology’s value. The authors find risk-sharing makes sense in 9 out of 16 scenarios, setting out the conditions in which both parties should use them. Innovators need to fund the research in order to align incentives.
As a Charity, OHE is governed by a Board of Trustees which today is comprised of a mixture of academic and industry experts. OHE has been privileged to have many leading health economists serving on its Boards and Committees over the nearly 60 years of its existence.
As US policymakers consider the potential implications of the drug pricing reforms contained within the Build Back Better Act, OHE releases a critique of the Congressional Budget Office scoring, demonstrating that the estimates are highly uncertain and policymakers should exercise caution when relying upon them.
OHE’s Chris Sampson is leading a new Research Topic published in Frontiers in Health Services, titled ‘Opportunity Costs in Health Care: Cost-effectiveness Thresholds and Beyond’. The Research Topic is open for submissions, and the editors are inviting research and commentary on a range of issues that the OHE team has been tackling for many years.
